Cancer of the Head and NeckNCT02073032
Incidence and Risk Factors of Refeeding Syndrome
An observational study of Cancer of the Head and Neck, run by University of Copenhagen at 1 site in Denmark.
Trial summary
The main objective of this observational survey was to determine the incidence rate of refeeding phenomena (RFF) (defined as any decline in p-phosphate) and RFS (defined as any decline in p-phosphate with additional development of any of the following clinical symptoms: oedema, confusion, dyspnoea, hypotension… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer of the Head and Neck
- How many people
- 79 participants
- Where
- 1 siteDenmark
- Study dates
- Feb 2011to Aug 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Referred for surgery with head and neck cancer
Who may be able to join
- Head and Neck Cancer
Who cannot join
- Not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Clinic for Ear, Nose and Throat Surgery, Rigshospital
Copenhagen, 2100 Cph OE
About this study
Official title: Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients - An Observational Study
The main objective of this observational survey was to determine the incidence rate of refeeding phenomena (RFF) (defined as any decline in p-phosphate) and RFS (defined as any decline in p-phosphate with additional development of any of the following clinical symptoms: oedema, confusion, dyspnoea, hypotension, arrhythmia, seizures) among recently admitted or referred HNC patients to the Department of Otorhinolaryngology for surgery. The second objective was to determine if informations at admittance could identify HNC patients at high risk of developing RFF and RFS.
Read the detailed description
Consecutive patients referred to the Department of Otorhinolaryngology and Audiology on suspicion of cancer during the study period from February to August 2011. Patients were asked for participation if they met the following inclusion criteria: age ≥ 18 years, suspicion or diagnosis with HNC, and first time referral. Patients were excluded if not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Every participant was observed for eight days after admission or referral to the clinic. Blood samples and interviews were performed at baseline and at day 2, 4 and 7.
Potential factors defining high risk were analyzed by comparing those patients developing RFS or RFF with those that did not. Baseline information consisted of data from the interview and supplemental information in medical records. As a part of the interview, the participant was asked about dietary history in order to assess daily habitual energy end protein intake. Hand grip strength (HGS) was measured, and the participant performed a maximal step test on a 20 cm high bench. The nutritional status was evaluated using the NRS-2002 screening tool (13) and refeeding risk according to the NICE-guidelines (14). Intake of energy, protein, and fluids was registered and compared to the estimated requirements. Standardized questionnaires were used for the interviews, and blood samples were analyzed as part of daily routine in in-patients, while outpatients had their blood samples collected by their general practitioner or by accredited hospital laboratories close to their homes. For participants with a body mass index (BMI) < 30 kg/m2, energy requirement was calculated using Harris \& Benedict's equations for men and women respectively (15). A physical activity factor of 1.1 for bedridden participants and 1.3 for non-bedridden participants was used. Protein requirement was calculated as 18 E-% of total energy requirement. For participants with a BMI ≥ 30 kg/m2 the following equations were used: Energy requirement (bedridden) = 85 kJ/kg body weight/day, energy requirement (non-bedridden) = 100kJ/kg body weight/day, protein requirement (bedridden) = 0.9 g/kg body weight/day, protein requirement (non-bedridden) = 1.1 g/kg body weight/day (16). Energy and protein intake was estimated from the 24-hour dietary recall by using the computer program "Dankost 3000" (Dankost 3000, version 2.5, Danish Catering Center, Herlev, Denmark).
For the step test, an audio file was used to dictate the rhythm, similar to the audio file used in The Danish Step Test (17). HGS was measured on the right hand with a hydraulic Jamar® hand dynamometer (scale 0-200 lbs). Three measurements were conducted with a break of 15 seconds between each measurement, and the mean value was used for analysis. Head and neck pain were measured twice by visual analogue scale (VAS) (18) with added marks for consistent pain and for pain during eating.
All statistical analyses were performed using STATA/IC 10.0 for Windows and Microsoft Excel 2003. The Mann-Whitney rank sum test was used for group comparisons, and dose-response relationships were tested by the Spearman's rank correlation test. Potential risk factors were analyzed by the Chi2-test with Yates correction or the Fisher's exact test as appropriate.
The primary outcomes were changes in p-phosphate and the development of RFS-symptoms after start of nutritional intake. A discriminative value for a clinically relevant hypophosphatemia or decline in p-phosphate was estimated from the coherence between the development of clinical symptoms and the lowest p-phosphate as well as the change in p-phosphate from baseline to the study day with the lowest p-phosphate value.
In case of significant differences between groups, odds ratios (OR) were calculated and Spearman's rank correlation test was used to test for correlation between the potential risk factor and change in p-phosphate, and correlations were tested for linearity by linear regression analysis. Sensitivity, specificity, and predictive values were calculated for NRS-2002 total score ≥ 3, NRS-2002 A-score = 1 and NICE guidelines, respectively.
The maximal increase in energy intake to be allowed without causing RFS was analyzed by correlating changes in p-phosphate and changes in intake in percentage of calculated energy requirements.
- Conditions
- Cancer of the Head and Neck
- Being tested
- No intervention, only observation
- Keywords
- Refeeding syndrome, risk factors, head and neck cancer
- Medical subject headings
- Head and Neck Neoplasms, Refeeding Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention, only observationOther
| Study group | Role | What they receive |
|---|---|---|
| Head -Neck cancer patients, no intervention | Not described Receives: Other: No intervention, only observation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Decrease in plasma phosphate after start of feeding
Plasma phosphate measured every day the initial day of feeding after admission
Measured: 1 week
Secondary outcomes (1)
Occurence of relevant clinical symptoms along with a decrease in plasma phosphate
Daily registration of symptoms: oedema, confusion, dyspnoea, hypotension, arrhythmia, seizures
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2014 (estimated)
- Study startFeb 2011
- Primary completionAug 2011
- Study completionAug 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cancer of the Head and NeckStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 79 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jens Rikardt Andersen, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02073032
- Sponsor's protocol ID
- JRA-refeed-1
- Status last verified
- Feb 2014
- First submitted
- 24 Feb 2014
- Last updated
- 27 Feb 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Rasmussen SO, Kristensen MB, Wessel I, Andersen JR. Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients-An Observational Study. Nutr Cancer. 2016 Nov-Dec;68(8):1320-1329. doi: 10.1080/01635581.2016.1225103. Epub 2016 Sep 28.
PubMed 27682582
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients - An Observational Study
- ClinicalTrials.gov ID
- NCT02073032
- Acronym / sponsor ID
- JRA-refeed-1
- Conditions
- Cancer of the Head and Neck
- Keywords
- Refeeding syndrome, risk factors, head and neck cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 79 participants (actual)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Study start
- Feb 2011
- Primary completion
- Aug 2011 (actual)
- Study completion
- Aug 2011 (actual)
- First posted
- 27 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this observational survey was to determine the incidence rate of refeeding phenomena (RFF) (defined as any decline in p-phosphate) and RFS (defined as any decline in p-phosphate with additional development of any of the following clinical symptoms: oedema, confusion, dyspnoea, hypotension, arrhythmia, seizures) among recently admitted or referred HNC patients to the Department of Otorhinolaryngology for surgery. The second objective was to determine if informations at admittance could identify HNC patients at high risk of developing RFF and RFS.
Detailed description
Consecutive patients referred to the Department of Otorhinolaryngology and Audiology on suspicion of cancer during the study period from February to August 2011. Patients were asked for participation if they met the following inclusion criteria: age ≥ 18 years, suspicion or diagnosis with HNC, and first time referral. Patients were excluded if not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Every participant was observed for eight days after admission or referral to the clinic. Blood samples and interviews were performed at baseline and at day 2, 4 and 7.
Potential factors defining high risk were analyzed by comparing those patients developing RFS or RFF with those that did not. Baseline information consisted of data from the interview and supplemental information in medical records. As a part of the interview, the participant was asked about dietary history in order to assess daily habitual energy end protein intake. Hand grip strength (HGS) was measured, and the participant performed a maximal step test on a 20 cm high bench. The nutritional status was evaluated using the NRS-2002 screening tool (13) and refeeding risk according to the NICE-guidelines (14). Intake of energy, protein, and fluids was registered and compared to the estimated requirements. Standardized questionnaires were used for the interviews, and blood samples were analyzed as part of daily routine in in-patients, while outpatients had their blood samples collected by their general practitioner or by accredited hospital laboratories close to their homes. For participants with a body mass index (BMI) < 30 kg/m2, energy requirement was calculated using Harris \& Benedict's equations for men and women respectively (15). A physical activity factor of 1.1 for bedridden participants and 1.3 for non-bedridden participants was used. Protein requirement was calculated as 18 E-% of total energy requirement. For participants with a BMI ≥ 30 kg/m2 the following equations were used: Energy requirement (bedridden) = 85 kJ/kg body weight/day, energy requirement (non-bedridden) = 100kJ/kg body weight/day, protein requirement (bedridden) = 0.9 g/kg body weight/day, protein requirement (non-bedridden) = 1.1 g/kg body weight/day (16). Energy and protein intake was estimated from the 24-hour dietary recall by using the computer program "Dankost 3000" (Dankost 3000, version 2.5, Danish Catering Center, Herlev, Denmark).
For the step test, an audio file was used to dictate the rhythm, similar to the audio file used in The Danish Step Test (17). HGS was measured on the right hand with a hydraulic Jamar® hand dynamometer (scale 0-200 lbs). Three measurements were conducted with a break of 15 seconds between each measurement, and the mean value was used for analysis. Head and neck pain were measured twice by visual analogue scale (VAS) (18) with added marks for consistent pain and for pain during eating.
All statistical analyses were performed using STATA/IC 10.0 for Windows and Microsoft Excel 2003. The Mann-Whitney rank sum test was used for group comparisons, and dose-response relationships were tested by the Spearman's rank correlation test. Potential risk factors were analyzed by the Chi2-test with Yates correction or the Fisher's exact test as appropriate.
The primary outcomes were changes in p-phosphate and the development of RFS-symptoms after start of nutritional intake. A discriminative value for a clinically relevant hypophosphatemia or decline in p-phosphate was estimated from the coherence between the development of clinical symptoms and the lowest p-phosphate as well as the change in p-phosphate from baseline to the study day with the lowest p-phosphate value.
In case of significant differences between groups, odds ratios (OR) were calculated and Spearman's rank correlation test was used to test for correlation between the potential risk factor and change in p-phosphate, and correlations were tested for linearity by linear regression analysis. Sensitivity, specificity, and predictive values were calculated for NRS-2002 total score ≥ 3, NRS-2002 A-score = 1 and NICE guidelines, respectively.
The maximal increase in energy intake to be allowed without causing RFS was analyzed by correlating changes in p-phosphate and changes in intake in percentage of calculated energy requirements.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Head -Neck cancer patients, no intervention | – | Other: No intervention, only observation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Referred for surgery with head and neck cancer
Key inclusion criteria (1 listed)
- Head and Neck Cancer
Key exclusion criteria (1 listed)
- Not able to understand and speak Danish, having severe dementia and/or renal impairment (women: p-creatinine > 180 μmol/l, men: p-creatinine > 200 μmol/l).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention, only observation | Other | Head -Neck cancer patients, no intervention |
Primary outcome
Decrease in plasma phosphate after start of feeding
Time frame: 1 week
Plasma phosphate measured every day the initial day of feeding after admission
1 secondary outcome
Occurence of relevant clinical symptoms along with a decrease in plasma phosphate
Time frame: 1 week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2014.
- Derived from this study: PubMed 27682582Rasmussen SO, Kristensen MB, Wessel I, Andersen JR. Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients-An Observational Study. Nutr Cancer. 2016 Nov-Dec;68(8):1320-1329. doi: 10.1080/01635581.2016.1225103. Epub 2016 Sep 28.
Related trials for Cancer of the Head and Neck
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
RecruitingObservational study
A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy
Head and Neck Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer of the Head and Neck, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Decrease in plasma phosphate after start of feeding (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02073032, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2014.